Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Contact Aldo Castagnari

From: Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option

Contact corresponding author